{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T08:37:31Z","timestamp":1649147851058},"reference-count":26,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[1999,3,1]],"date-time":"1999-03-01T00:00:00Z","timestamp":920246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1999,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            A study was designed to determine if an isogenic panel of\n            <jats:italic>Escherichia coli<\/jats:italic>\n            strains containing many different \u03b2-lactamases could be used for the preliminary screening of a large number of \u03b2-lactam agents to identify which might be most useful in the development of a definitive test for specific \u03b2-lactamases found among the members of family\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            . The susceptibilities of 46 strains, comprising the isogenic panel, to expanded-spectrum cephalosporins, cephamycins, and aztreonam were determined in the presence and absence of \u03b2-lactamase inhibitors in broth microdilution tests. The results indicated that strains producing extended-spectrum \u03b2-lactamases (ESBLs) could be distinguished from strains producing other Bush-Jacoby-Medeiros functional group 2 or group 1 \u03b2-lactamases. For strains producing group 1 \u03b2-lactamases, cefpodoxime and ceftazidime MICs were \u22654 \u03bcg\/ml and addition of clavulanate did not reduce the MICs more than fourfold. For strains producing group 2 enzymes other than ESBLs, cefpodoxime and ceftazidime MICs were \u22642 \u03bcg\/ml. With a single exception (ceftazidime for the strain producing SHV-3), among strains producing ESBLs, cefpodoxime and ceftazidime MICs were \u22654 \u03bcg\/ml and addition of clavulanate reduced the MICs by more than eightfold. Cephamycins could also be used to discriminate between strains producing group 1 \u03b2-lactamases and ESBLs, since only the former required cefotetan concentrations as high as 8 \u03bcg\/ml or cefoxitin concentrations of &gt;16 \u03bcg\/ml for inhibition. Other cephalosporins provided some discrimination between the various \u03b2-lactamase producers, although they were not as reliable as either cefpodoxime or ceftazidime. These results indicate the utility of an isogenic panel for identification of candidate drugs among many for further testing with clinical isolates of the family\n            <jats:italic>Enterobacteriaceae<\/jats:italic>\n            to determine the best agents for detection of specific \u03b2-lactamases in this family.\n          <\/jats:p>","DOI":"10.1128\/aac.43.3.630","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:34:19Z","timestamp":1539045259000},"page":"630-633","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["Use of an Isogenic\n            <i>Escherichia coli<\/i>\n            Panel To Design Tests for Discrimination of \u03b2-Lactamase Functional Groups of\n            <i>Enterobacteriaceae<\/i>"],"prefix":"10.1128","volume":"43","author":[{"given":"Anton F.","family":"Ehrhardt","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology, Creighton University School of Medicine, Omaha, Nebraska 68178"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine C.","family":"Sanders","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology, Creighton University School of Medicine, Omaha, Nebraska 68178"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen S.","family":"Moland","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology, Creighton University School of Medicine, Omaha, Nebraska 68178"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.179.6.2006-2013.1997"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.1.260"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.308"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.4.899"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.3.259"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1211"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.34.8.1880-1884.1996"},{"key":"e_1_3_2_9_2","unstructured":"Ehrhardt\n              A. F.\n              Sanders\n              C. C.\n              Moland\n              E. S.\n          Use of an isogenic Escherichia coli panel in designing tests for \u03b2-lactamase detection abstr. D-16\n          Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy.\n          1997\n          86\n          American Society for Microbiology\n          Washington D.C"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.9.2150"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.32.3.691-696.1994"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.5.715"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2488"},{"key":"e_1_3_2_14_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4.\n          1997\n          National Committee for Clinical Laboratory Standards\n          Villanova Pa"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.962"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01690097"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/infdis\/159.5.1005","article-title":"In vivo selection of a cephamycin resistant porin mutant of a CTX-1 \u03b2-lactamase producing strain of Klebsiella pneumoniae.","volume":"159","author":"Pangon B.","year":"1989","unstructured":"Pangon B. Bizet C. Pichon F. Philippon A. Regnier B. Bure A. Gutmann L. In vivo selection of a cephamycin resistant porin mutant of a CTX-1 \u03b2-lactamase producing strain of Klebsiella pneumoniae. J. Infect. Dis. 159 1989 1005 1006","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_18_2","unstructured":"Pitout\n              J. D. D.\n              Moland\n              E. S.\n              Sanders\n              C. C.\n          Changes in porin expression associated with the stepwise increase in resistance to cefoxitin in Klebsiella pneumoniae involved in nosocomial infections abstr. C39\n          Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy.\n          1996\n          41\n          American Society for Microbiology\n          Washington D.C"},{"key":"e_1_3_2_19_2","unstructured":"Sambrook\n              J.\n              Fritsch\n              E. F.\n              Maniatus\n              T.\n          Molecular cloning: a laboratory manual\n          2nd ed.\n          1989\n          Cold Spring Harbor Laboratory Press\n          Cold Spring Harbor N.Y"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.34.12.2997-3001.1996"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/clind\/15.5.824","article-title":"\u03b2-lactam resistance in gram-negative bacteria: global trends and clinical impact.","volume":"15","author":"Sanders C. C.","year":"1992","unstructured":"Sanders C. C. Sanders W. E. Jr. \u03b2-lactam resistance in gram-negative bacteria: global trends and clinical impact. Clin. Infect. Dis. 15 1992 824 839","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_22_2","unstructured":"Thomson\n              K. S.\n              Moland\n              E. S.\n              Sanders\n              C. C.\n          Use of microdilution panels with and without \u03b2-lactamase inhibitors as a specific test for \u03b2-lactamase production (\u03b2L+) among E. coli and Klebsiella abstr. D-17\n          Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy.\n          1997\n          86\n          American Society for Microbiology\n          Washington D.C"},{"key":"e_1_3_2_23_2","first-page":"151","article-title":"Novel plasmid-mediated \u03b2-lactamases in Enterobacteriaceae: emerging problems for new \u03b2-lactam antibiotics","volume":"16","author":"Thomson K. S.","year":"1996","unstructured":"Thomson K. S. Prevan A. M. Sanders C. C. Novel plasmid-mediated \u03b2-lactamases in Enterobacteriaceae: emerging problems for new \u03b2-lactam antibiotics Current clinical topics in infectious diseases Remington J. S. Swartz M. N. 16 1996 151 163 Blackwell Science, Inc. Cambridge, Mass","journal-title":"Current clinical topics in infectious diseases"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.1997.tb00306.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.9.2207"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.35.9.2191-2197.1997"},{"key":"e_1_3_2_27_2","unstructured":"Yang\n              Y.\n              Bhachech\n              N.\n              Bradford\n              P. A.\n              Jett\n              B. D.\n              Sahm\n              D. F.\n              Bush\n              K.\n          Ceftazidime-resistant Klebsiella pneumoniae and E. coli isolates producing TEM-10 and TEM-43 \u03b2-lactamases from St. Louis abstr. C25\n          Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy.\n          1996\n          38\n          American Society for Microbiology\n          Washington D.C"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.3.630","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.3.630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:10:31Z","timestamp":1645459831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.43.3.630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["10.1128\/AAC.43.3.630"],"URL":"https:\/\/doi.org\/10.1128\/aac.43.3.630","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,3]]},"assertion":[{"value":"1998-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-12-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}